<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="27584,30834">Aldosterone</z:chebi> levels are high early after admission for ST elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>) concomitantly with high risk of <z:hpo ids='HP_0001699'>sudden death</z:hpo> and life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We assessed the hypothesis that early <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockade on admission for primary percutaneous coronary intervention (PCI) may be associated with a reduction of life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> in a prospective cohort-nested case (n=159) versus historical control (n=623) study </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases were treated on admission by 200mg IV bolus of <z:chebi fb="120" ids="26216">potassium</z:chebi> <z:chebi fb="0" ids="50159">canrenoate</z:chebi>, followed by 25mg PO <z:chebi fb="0" ids="9241">spironolactone</z:chebi> daily during the coronary care unit stay </plain></SENT>
<SENT sid="3" pm="."><plain>The primary endpoint - in-hospital composite of <z:hpo ids='HP_0011420'>death</z:hpo>, resuscitated <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> and <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> - was assessed by logistic regression models adjusted on major pre-specified variables and validated by a bootstrap procedure and propensity-score based analyses </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="27584,30834">Aldosterone</z:chebi> blockade was associated with lower risks of the primary endpoint (adjusted ORs 0.26, 95% CI [0.13-0.57]), resuscitated <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> (adjusted OR 0.39, 95% CI [0.16-0.94]), <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> or <z:mp ids='MP_0006109'>fibrillation</z:mp> (adjusted ORs 0.23, 95% CI [0.12-0.45]), as well as <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> requiring resuscitation or anti-arrhythmic therapy (adjusted OR 0.41, 95% CI [0.19-0.88]) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> findings were confirmed by the bootstrap procedure </plain></SENT>
<SENT sid="6" pm="."><plain>The benefit on <z:hpo ids='HP_0011420'>death</z:hpo> or resuscitated <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> seemed sustained at 6month follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Early <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockade in patients presenting for primary PCI for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> is associated with significant reductions in rates of life-threatening <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> and <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> independent of the initial risk profile, <z:hpo ids='HP_0001635'>heart failure</z:hpo> or hemodynamic status </plain></SENT>
<SENT sid="8" pm="."><plain>These findings support the concept of <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockade early after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>, warranting further confirmation by ongoing randomized trials </plain></SENT>
</text></document>